[Codi: CU-40102 (finasteride spray for topical use) has received marketing approval from the Macau Food and Drug Administration] On September 21, Codi Group announced on the Hong Kong Stock Exchange that the group’s CU-40102 (finasteride spray for topical use) has received marketing approval from the Food and Drug Administration of the People’s Republic of China (Macau Special Administrative Region Government). The approved indication is the treatment of androgenetic alopecia. This is the second step for CU-40102 to obtain approval from the Chinese Food and Drug Administration. This is another major development after being approved by the National Medical Products Administration and the Department of Health of the Government of the Hong Kong Special Administrative Region of China. Finasteride acts as a specific competitive inhibitor of type II 5α-reductase to inhibit the conversion of testosterone into dihydrotestosterone in the scalp and can treat androgenic alopecia. Unlike oral finasteride, the topical formulation of CU-40102 allows patients to apply the drug directly and accurately to the scalp surface, which can reduce the systemic exposure of the drug compared with oral medications.